EP1181555A4 - Krebsbehandlung mit antagonisten des endothelinrezeptors - Google Patents

Krebsbehandlung mit antagonisten des endothelinrezeptors

Info

Publication number
EP1181555A4
EP1181555A4 EP00932027A EP00932027A EP1181555A4 EP 1181555 A4 EP1181555 A4 EP 1181555A4 EP 00932027 A EP00932027 A EP 00932027A EP 00932027 A EP00932027 A EP 00932027A EP 1181555 A4 EP1181555 A4 EP 1181555A4
Authority
EP
European Patent Office
Prior art keywords
present
receptor antagonists
cancer treatment
cancer
endothelin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP00932027A
Other languages
English (en)
French (fr)
Other versions
EP1181555B1 (de
EP1181555A1 (de
Inventor
Robert J Schneider
Sumayah Jamal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
Original Assignee
New York University NYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University NYU filed Critical New York University NYU
Priority to EP20050019232 priority Critical patent/EP1609484B1/de
Publication of EP1181555A1 publication Critical patent/EP1181555A1/de
Publication of EP1181555A4 publication Critical patent/EP1181555A4/de
Application granted granted Critical
Publication of EP1181555B1 publication Critical patent/EP1181555B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57536—Endothelin, vasoactive intestinal contractor [VIC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5754—Endothelin, vasoactive intestinal contractor [VIC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
EP00932027A 1999-05-04 2000-05-03 Krebsbehandlung mit antagonisten des endothelinrezeptors Expired - Lifetime EP1181555B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP20050019232 EP1609484B1 (de) 1999-05-04 2000-05-03 Krebsbehandlung mit Antagonisten des Endothelinrezeptors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/305,084 US7566452B1 (en) 1999-05-04 1999-05-04 Cancer treatment with endothelin receptor antagonists
US305084 1999-05-04
PCT/US2000/011990 WO2000067024A1 (en) 1999-05-04 2000-05-03 Cancer treatment with endothelin receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP20050019232 Division EP1609484B1 (de) 1999-05-04 2000-05-03 Krebsbehandlung mit Antagonisten des Endothelinrezeptors

Publications (3)

Publication Number Publication Date
EP1181555A1 EP1181555A1 (de) 2002-02-27
EP1181555A4 true EP1181555A4 (de) 2003-03-26
EP1181555B1 EP1181555B1 (de) 2008-12-24

Family

ID=23179263

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00932027A Expired - Lifetime EP1181555B1 (de) 1999-05-04 2000-05-03 Krebsbehandlung mit antagonisten des endothelinrezeptors
EP20050019232 Expired - Lifetime EP1609484B1 (de) 1999-05-04 2000-05-03 Krebsbehandlung mit Antagonisten des Endothelinrezeptors

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP20050019232 Expired - Lifetime EP1609484B1 (de) 1999-05-04 2000-05-03 Krebsbehandlung mit Antagonisten des Endothelinrezeptors

Country Status (8)

Country Link
US (4) US7566452B1 (de)
EP (2) EP1181555B1 (de)
AT (1) ATE418732T1 (de)
AU (1) AU4981500A (de)
CA (1) CA2370252C (de)
DE (1) DE60041185D1 (de)
ES (1) ES2319724T3 (de)
WO (1) WO2000067024A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
ES2384208T3 (es) 2001-11-01 2012-07-02 Spectrum Pharmaceuticals, Inc. Composiciones medicinales para el tratatamiento intravesical del cáncer de vejiga.
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
US8217010B2 (en) 2002-10-24 2012-07-10 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
US20040138121A1 (en) * 2002-10-24 2004-07-15 Anil Gulati Method and composition for preventing and treating solid tumors
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
CN101534852B (zh) 2006-08-31 2013-02-13 光谱医药公司 通过施用内皮素激动剂使得肿瘤细胞对放疗敏化
US9289426B2 (en) * 2007-03-21 2016-03-22 University Of Pennsylvania Methods and compositions for treating solid tumors and enhancing tumor vaccines
EP2538981B1 (de) * 2010-02-23 2017-12-20 F. Hoffmann-La Roche AG Zusammensetzungen und methoden zur diagnose und behandlung von tumoren
FR2965810B1 (fr) * 2010-10-06 2012-12-28 Commissariat Energie Atomique Anticorps antagoniste du sous-type b des recepteurs aux endothelines et ses utilisations
WO2013063001A1 (en) * 2011-10-28 2013-05-02 Genentech, Inc. Therapeutic combinations and methods of treating melanoma
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
BR112015002193A2 (pt) 2012-08-02 2017-07-04 Genentech Inc anticorpos anti-etbr e imunoconjugados
KR20150032886A (ko) 2012-08-02 2015-03-30 제넨테크, 인크. 항-etbr 항체 및 면역접합체
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
WO2017024032A2 (en) 2015-08-03 2017-02-09 Enb Therapeutics, Llc Compositions and methods for treating cancers associated with etbr activation
FR3053042B1 (fr) 2016-06-24 2018-08-10 Commissariat A L'energie Atomique Et Aux Energies Alternatives Anticorps dirige contre le sous-type b des recepteurs aux endothelines et ses utilisations
EP3692369A1 (de) * 2017-10-02 2020-08-12 Universität zu Köln Tumor- und metastasierungsmarker
MX2020007293A (es) * 2018-01-12 2021-01-08 Enb Therapeutics Inc Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr.
CA3166826A1 (en) * 2020-01-06 2021-07-15 Lassogen, Inc. Lasso peptides for treatment of cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499266A1 (de) * 1991-02-15 1992-08-19 Takeda Chemical Industries, Ltd. Endothelin Antagoniste
EP0801062A1 (de) * 1994-12-28 1997-10-15 Kowa Co. Ltd. Pyrimidin-derivate
WO1998041206A1 (en) * 1997-03-14 1998-09-24 Basf Aktiengesellschaft Novel carboxylic acid derivatives, their preparation and use in treating cancer
WO2000036918A1 (en) * 1998-12-22 2000-06-29 Marine Polymers Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
WO2001000198A2 (en) * 1999-06-29 2001-01-04 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor of endothelin receptor activity

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190496A (en) 1971-05-14 1980-02-26 Syva Company Homogeneous enzyme assay for antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5571821A (en) 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5082838A (en) 1989-06-21 1992-01-21 Takeda Chemical Industries, Ltd. Sulfur-containing fused pyrimidine derivatives, their production and use
JPH0347163A (ja) 1989-06-30 1991-02-28 Fujisawa Pharmaceut Co Ltd アントラキノン誘導体およびその製造
EP0444181B2 (de) * 1989-08-04 2010-11-24 Bayer Schering Pharma Aktiengesellschaft Äusserliche domäne von c-erbb-2:gp75
CA2032559C (en) 1989-12-28 2001-11-06 Kiyofumi Ishikawa Endothelin antagonistic cyclic pentapeptides
AU660629B2 (en) 1990-10-01 1995-07-06 University Of Connecticut, The Targeting viruses and cells for selective internalization by cells
US5736509A (en) * 1990-12-14 1998-04-07 Texas Biotechnology Corporation Cyclic peptide surface feature mimics of endothelin
CA2059380A1 (en) 1991-01-24 1992-07-25 Yiu-Kuen T. Lam Endothelin receptor antagonists isolated from microbispora
JP2950616B2 (ja) 1991-01-29 1999-09-20 塩野義製薬株式会社 トリテルペン誘導体
TW270116B (de) 1991-04-25 1996-02-11 Hoffmann La Roche
ATE199647T1 (de) 1991-05-14 2001-03-15 Univ Connecticut Gerichtete abgabe von genen, die immunogene proteine kodieren
US5382569A (en) 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
WO1992022635A1 (en) 1991-06-05 1992-12-23 University Of Connecticut Targeted delivery of genes encoding secretory proteins
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
FR2679906B1 (fr) 1991-07-31 1995-01-20 Adir Nouvelles (isoquinolein-5 yl) sulfonamides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO1993008799A1 (en) 1991-11-05 1993-05-13 Smithkline Beecham Corporation Endothelin receptor antagonists
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5198548A (en) 1992-01-30 1993-03-30 Warner-Lambert Company Process for the preparation of D(-) and L(+)-3,3-diphenylalanine and D(-) and L(+)-substituted 3,3-diphenylalanines and derivatives thereof
TW224462B (de) 1992-02-24 1994-06-01 Squibb & Sons Inc
EP0633943A4 (de) 1992-04-03 1997-05-02 Alexander T Young Gentherapy unter verwendung zielgerichteter viraler vektoren.
US5240910A (en) 1992-04-17 1993-08-31 Merck & Co., Inc. Antihypertensive compounds produced by fermentation
US5550110A (en) 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5352800A (en) 1993-03-11 1994-10-04 Merck & Co., Inc. Process for the production of a novel endothelin antagonist
US5334598A (en) 1993-03-19 1994-08-02 Merck & Co., Inc. Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
DE4411225A1 (de) 1994-03-31 1995-10-05 Basf Ag Verwendung von Carbonsäurederivaten als Arzneimittel
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US5573762A (en) * 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
US5968981A (en) * 1995-07-28 1999-10-19 The Regents Of The University Of California Retinoid suppression of ventricular muscle cell hypertrophy
DE19614542A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614534A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614533A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19636046A1 (de) 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
US6673832B1 (en) * 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499266A1 (de) * 1991-02-15 1992-08-19 Takeda Chemical Industries, Ltd. Endothelin Antagoniste
EP0801062A1 (de) * 1994-12-28 1997-10-15 Kowa Co. Ltd. Pyrimidin-derivate
WO1998041206A1 (en) * 1997-03-14 1998-09-24 Basf Aktiengesellschaft Novel carboxylic acid derivatives, their preparation and use in treating cancer
WO2000036918A1 (en) * 1998-12-22 2000-06-29 Marine Polymers Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
WO2001000198A2 (en) * 1999-06-29 2001-01-04 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor of endothelin receptor activity

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
KIKUCHI K ET AL: "DECREASED ETB RECEPTOR EXPRESSION IN HUMAN METASTATIC MELANOMA CELLS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 219, no. 3, 1996, pages 734 - 739, XP002931328, ISSN: 0006-291X *
LI M H ET AL: "Antisense oligodeoxynucleotide of endothelin-1 inhibits mesangial cell proliferation in vitro and in vivo.", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 8, no. PROGRAM AND ABSTR. ISSUE, 1997, 30th Annual Meeting of the American Society of Nephrology;San Antonio, Texas, USA; November 2-5, 1997, pages 477A, XP002227878, ISSN: 1046-6673 *
MORAITIS S ET AL: "Endothelin expression and responsiveness in human ovarian carcinoma cell lines.", EUROPEAN JOURNAL OF CANCER (OXFORD, ENGLAND: 1990) ENGLAND APR 1997, vol. 33, no. 4, April 1997 (1997-04-01), pages 661 - 668, XP004282572, ISSN: 0959-8049 *
NELSON J B ET AL: "ENDOTHELIN-1 PRODUCTION AND DECREASED ENDOTHELIN B RECEPTOR EXPRESSION IN ADVANCED PROSTATE CANCER", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 56, no. 4, 15 February 1996 (1996-02-15), pages 663 - 668, XP001026084, ISSN: 0008-5472 *
OHNO A ET AL: "Endothelin-specific antibodies decrease blood pressure and increase glomerular filtration rate and renal plasma flow in spontaneously hypertensive rats.", JOURNAL OF HYPERTENSION. ENGLAND AUG 1992, vol. 10, no. 8, August 1992 (1992-08-01), pages 781 - 785, XP008012734, ISSN: 0263-6352 *
OKAZAWA M ET AL: "ENDOTHELIN-INDUCED APOPTOSIS OF A375 HUMAN MELANOMA CELLS", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 273, no. 20, 15 May 1998 (1998-05-15), pages 12584 - 12592, XP001026098, ISSN: 0021-9258 *
STAVROS F D ET AL: "COS-7 cells stably transfected to express the human ET-B receptor provide a useful screen for endothelin receptor antagonists.", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 22, no. SUPPL. 8, 1993, pages S34 - S37, XP008012413, ISSN: 0160-2446 *

Also Published As

Publication number Publication date
US20130309253A1 (en) 2013-11-21
WO2000067024A1 (en) 2000-11-09
ES2319724T3 (es) 2009-05-12
EP1609484A1 (de) 2005-12-28
US20120148602A1 (en) 2012-06-14
US8597645B2 (en) 2013-12-03
EP1609484B1 (de) 2013-05-01
US7566452B1 (en) 2009-07-28
AU4981500A (en) 2000-11-17
US8067000B2 (en) 2011-11-29
CA2370252C (en) 2014-01-14
US20100003240A1 (en) 2010-01-07
EP1181555B1 (de) 2008-12-24
EP1181555A1 (de) 2002-02-27
CA2370252A1 (en) 2000-11-09
DE60041185D1 (de) 2009-02-05
ATE418732T1 (de) 2009-01-15
US9125897B2 (en) 2015-09-08
WO2000067024A9 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
EP1181555A4 (de) Krebsbehandlung mit antagonisten des endothelinrezeptors
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
FI974368A (fi) Kasvuhormonin vapautumista edistäviä dipeptidejä
NO983002L (no) Vitronectin-reseptor-antagonister
SE9604793D0 (sv) New polymorphs
DE69732868D1 (de) Mittel gegen Juckreiz
NO20010446L (no) Substituert anilidforbindelser og metoder
DE69936100D1 (de) Somatostatin-analoge mit einer zyklisierten konformationsbeschränkten hauptkette
DE69905476D1 (en) Phosphonsaürederivate als ptp-1b-inhibitoren
WO2002064125A3 (en) Use of a farnesoid x receptor antagonist for treating hyperlipidemia
ATE357917T1 (de) Behandlung von dyskinesie durch mu-selektive opioidantagonisten
DK0989973T3 (da) Chalconer med antiproliferativ aktivitet
ATE288268T1 (de) Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethoden
AU2001233913A1 (en) Bcmp 84, a protein associated to breast cancer
AU2001245209A1 (en) Screening methods for bone morphogenetic mimetics
HK1037141A1 (en) Use of endothelin receptor antagonists for producing drugs for controlling obesity.
TR200103638T2 (tr) IL-8 Reseptör antagonistleri
DE69718146T2 (de) At1 rezeptor antagonist zur anregung von apoptosis
WO2002059356A3 (en) Method for screening compounds for activity in treating an osteoclast related bone disease
DK0836538T3 (da) Fremgangsmåde til bortskaffelse af affald fra transdermal indgivelse af aktivt stof
AU2003282035A1 (en) Modulation of s6 kinase activity for the treatment of obestiy
NZ505085A (en) Pharmaceutical compositions comprising bipapcitide monocarboxylate and/or bipapcitide dicarboxylate for imaging and treating thrombi
DE60111571D1 (de) Verwendung von anethol-dithiolethion zur vorbeugung und behandlung der sehnentoxizität
GB0213698D0 (en) Receptor
MXPA01009174A (es) Antagonistas de endotelina novedosos derivados de piridazina.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/00 B

Ipc: 7C 07K 5/00 B

Ipc: 7C 07K 4/00 B

Ipc: 7G 01N 33/567 B

Ipc: 7C 07K 2/00 B

Ipc: 7C 07K 17/00 B

Ipc: 7A 61K 38/18 B

Ipc: 7A 61K 38/00 B

Ipc: 7C 07K 16/00 B

Ipc: 7C 07K 14/00 B

Ipc: 7G 01N 33/53 A

A4 Supplementary search report drawn up and despatched

Effective date: 20030207

17Q First examination report despatched

Effective date: 20030718

17Q First examination report despatched

Effective date: 20030718

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60041185

Country of ref document: DE

Date of ref document: 20090205

Kind code of ref document: P

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2319724

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081224

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081224

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090525

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081224

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090324

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081224

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20090925

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090531

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090531

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090325

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081224

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20180529

Year of fee payment: 19

Ref country code: ES

Payment date: 20180601

Year of fee payment: 19

Ref country code: IE

Payment date: 20180529

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20180525

Year of fee payment: 19

Ref country code: IT

Payment date: 20180522

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20180529

Year of fee payment: 19

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60041185

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20190503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190503

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191203

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190503

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190531

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20200925

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190504